The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

Immune responses to respiratory syncytial virus (RSV) vaccines tended to fall short in older people with weakened immunity, a study found. In 38 immunocompromised persons who received either the ...

While issuing its RSV warning mandate on Tuesday, the FDA added that the benefits of vaccination with Abrysvo and Arexvy “continue to outweigh their risks.” During an FDA advisory panel ...

The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...

Jason McLellan, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at UT, will be ...

The abrysvo or arexvy market's growth is expected to be significantly driven by the increasing prevalence of respiratory syncytial virus RSV infections. RSV infections primarily affect the ...

According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV ...